INTELLIGENCE: CAR-T CANCER IMMUNOTHERAPY PROMISING BUYOUT TARGETS AFTER ASTRAZENECA $AZN $CLLS $JUNO $BLCM $XON $ZIOP $KITE $BLUE $ADXS $LBIO
This post was just published on ZYX Buy Change Alert.
For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage.
AZN CEO has stated that he will consider buying a company such as JUNO.
The lure of JUNO is the progress it has made in CAR-T cancer immunotherapy. In this therapy, immune cells are manipulated with Chimeric Antigen Receptors to find and destroy cancer tumor cells without harming normal cells.… Please click here or the title below to read more.
June 2, 2015